Zacks Rating on Galena Biopharma (GALE)

Galena Biopharma (GALE) has an average broker rating of 2, which is interpreted as a Buy, as rated by 4 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 1, which is also a Strong Buy.


Shares of Galena Biopharma, Inc. appreciated by 9.68% during the last five trading days but lost 0.07% on a 4-week basis. Galena Biopharma, Inc. has dropped 74.16% during the last 3-month period . Year-to-Date the stock performance stands at -69.41%. Galena Biopharma (NASDAQ:GALE): stock turned positive on Tuesday. Though the stock opened at $0.44, the bulls momentum made the stock top out at $0.4552 level for the day. The stock recorded a low of $0.432 and closed the trading day at $0.4497, in the green by 3.12%. The total traded volume for the day was 4,675,098. The stock had closed at $0.4361 in the previous days trading.

Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug, Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.